Search
Anagrelide
go.drugbank.com/drugs/DB00261ApprovedInvestigationalAnagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. … [L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g.
Dextrothyroxine
go.drugbank.com/drugs/DB00509ApprovedWithdrawnThe major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (monoiodotyrosine) and the coupling of iodotyrosines (diiodotyrosine) in the thyroglobulin. … Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood.
Caroxazone
go.drugbank.com/drugs/DB09254ApprovedWithdrawnHowever, it presents a five-fold preference for the MAO-B subtype. … Caroxazone is an antidepressant that has been withdrawn from the market. It is a reversible monoamine oxidase inhibitor (MAOI) of both A and B monoamine oxidase subtypes.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeDifelikefalin
go.drugbank.com/drugs/DB11938ApprovedInvestigational[A237610] Further investigations revealed that dynorphins, endogenous agonists of KORs, work to inhibit the itching sensation at the spinal cord level, and scratching could be elicited in mouse models … [L36420,L36395] Difelikefalin was later approved by the EMA in April 2022 for the same indication.[L41665]
Categories: Kappa Opioid Receptor AgonistPraziquantel
go.drugbank.com/drugs/DB01058ApprovedInvestigationalVet approved[A263206,A263211] Despite being approved since 1980, the exact mechanism of action is yet to be elucidated.[A263211] … [A263201] The efficacy of praziquantel in treating parasitic flatworms infection with low cost (~US$0.20 drug cost to treat a child) makes it an integral to WHO's plan to eliminate schistosomiasis by 2030
Cefdinir
go.drugbank.com/drugs/DB00535ApprovedInvestigationalIt has been proven to be effective for the treatment of common bacterial infections in the ear, sinus, throat, lungs, and skin. … Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class.
Natalizumab
go.drugbank.com/drugs/DB00108ApprovedInvestigationalIn 2006, the FDA reintroduced the drug to the market for multiple sclerosis.[A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. … [A261331] On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA.[L48041] Natalizumab was approved by the European Commission on September 22, 2023.
Categories: Integrin Receptor AntagonistAcetyl sulfisoxazole
go.drugbank.com/drugs/DB14033ApprovedVet approvedSulfisoxazole acetyl competes with PABA for the bacterial enzyme, _dihydropteroate synthase_, preventing the incorporation of PABA into dihydrofolic acid, which is the precursor of folic acid. … It is often combined with erythromycin to treat acute otitis media caused by the bacteria, haemophilus influenzae [L2790].
Lumefantrine
go.drugbank.com/drugs/DB06708ApprovedInvestigational</i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas. … This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.
Elagolix
go.drugbank.com/drugs/DB11979ApprovedInvestigationalAs of 24 July 2018, however, the U.S. … Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801].
Categories: Gonadotropin Releasing Hormone Receptor Antagonists